MAO activity in serotonergic endings of rat major cerebral arteries
Tóm tắt
The present work studies the existence of monoamine oxidase (MAO) activity in serotonergic endings present in rat major cerebral arteries. Enzymatic activity was appraisedin vivo by serotonin (5-HT) accumulation or 5-hydroxyindole acetic acid (5-HIAA) disappearance with time after systemic administration of MAO inhibitors. Pargyline (75 mg/Kg, i.p.) brought about significant 5-HT increase and 5-HIAA decrease in major cerebral arteries 30 and 60 min after its administration. Clorgyline (75 mg/Kg, i. p.) also induced 5-HT enhancement and 5-HIAA decline in these arteries 30 and 60 min after its injection. However, treatment with deprenyl (75 mg/Kg, i. p.) only evoked a significant 5-HT increase at 60 min. When either clorgyline (5 mg/Kg, i. p.) or deprynyl (5 mg/Kg, i. p.) were administered 5-HT and 5-HIAA levels remained unaffected. Two weeks after performing electrolytical lesion of dorsal raphe nucleus and 60 min after clorgyline (75 mg/Kg, i. p.) injection 5-HT and 5-HIAA levels appeared significantly reduced in cerebral arteries and striatum when compared to sham-lesioned controls. These results suggest that MAO-A isoform acting on endogenous 5-HT is present in rat major cerebral arteries and is located in nerve endings of fibers arising from dorsal raphe nucleus.
Tài liệu tham khảo
Arai, R., Kimura, H., Nagatsu, I., and Maeda, T. (1997):Brain Res.,745, 352–356.
Aubineau, P. and Mathiau, P. (1995):Stroke,26, 139–140.
Bonvento, G., MacKenzie, E. T., Fage, D., Benavides, J., Rouquier, L. and Scatton, B. (1991):J. Neurochem.,56, 681–689.
Cohen, Z., Bonvento, G., Lacombe, P., Seylaz, J., MacKenzie, E. T. and Hamel, E. (1992):Brain Res.,598, 203–214.
Frazer, A., and Hensler, J. G. (1994): In “Basic Neurochemistry”. (Siegel, G. J., Agranoff, B. W., Albers, R. W., and Molinoff, P. B., eds.). Raven Press, New York, pp. 283–308.
Hardebo, J. E., Emson, P. C., Falck, B., Owman, C. and Rosengren, E. (1980):J. Neurochem.,35, 1388–1393.
Jahng, J. W., Houpt, T. A., Wessel, T. C., Chen, K., Shih, J. C., and Joh, T. H. (1997):Synapse,25, 30–36.
Kumagae, Y., Matsui, Y., and Iwata, N. (1991):Jpn. J. Pharmacol.,55, 121–128.
López de Pablo, A. L., Moreno, M. J. and Marco, E. J. (1996):J. Neurochem.,67, 2060–2065.
Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Randall, R. J. (1951):J. Biol. Chem.,193, 354–357.
Luque, J. M., Kwan, S.-W., Abell, C. W., Da Prada, M. and Richards, J. G. (1995):J. Comp. Neurol.,363, 665–680.
Mamounas, L. A., Mullen, C. A., O’Hearn, E. and Molliver, M. E. (1991):J. Comp. Neurol.,314, 558–586.
Marco, E. J., Moreno, M. J., and López de Pablo, A. L. (1999):Stroke,30, 1695–1701.
Moreno, M. J., López de Pablo, A. L., Conde, M. V., Fraile, M. L. and Marco, E. J. (1994):Rev. esp. Fisiol.,50, 175–181.
Moreno, M. J., López de Pablo, A. L., and Marco, E. J. (1994):Stroke,25, 1046–1049.
Moreno, M. J., López de Pablo, A. L., Conde, M. V. and Marco, E. J. (1995):Stroke,26, 271–275: discussion 275–276.
Moreno, M. J., López de Pablo, A. L. and Marco, E. J. (1997):Brain Res.,749, 161–163.
Neff, N. H., Lin, R. C., Ngai, S. H. and Costa, E. (1969):Adv. Biochem. Psychopharmacol.,1, 91–109.
Shigematsu, K., Akiguchi, I., Oka, N., Kamo, H., Matsubyashi, K., Kawamura, J. and Maeda, T. (1989):Brain Res.,497, 21–29.
Silver, H. and Youdim, M. B. (2000):Eur. Neuropsychopharmacol.,10, 125–128.
Soto, J. C. and Marco, E. J. (1988):J. Pharm. Pharmacol.,40, 185–187.
Standaert, D. G. and Young, A. B. (1996): In “Goodman & Gilman’s The Pharmacological Basis of Therapeutics” (Hardman, J. G., Gilman, G., and Limbird, L. E., eds.). McGraw-Hill, New York, pp. 503–519.
Youdin, M. B. H. and Finberg, J. P. M. (1983): In “Psychopharmacology. Part 1: Preclinical Psychopharmacology”. (Grahame-Smith, D. G., Hippius, H. and Winokur, G., eds.). Excerpta Medica, Amsterdam. pp. 38–70.